Claudin 18.2 靶向:泛癌视角
Claudin 18.2 Targeting: A Pan-Cancer Perspective.
FDA 对 zolbetuximab 批准的 CLDN18.2 阈值为 ≥ 75% 中度至强染色。
英文原题:Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma.
Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma.
在此,对72例接受原发切除或围手术期标准治疗FLOT的GEJ I和II腺癌患者的福尔马林固定石蜡包埋肿瘤切片,使用多重免疫组化分析了其瘤内T细胞组成。
胃食管交界处(GEJ)腺癌是一种日益常见的癌症,具有复杂的生物学特性和较差的预后。局部晚期肿瘤的治疗策略包括围手术期化疗的多模式治疗。然而,生存率仍然很低,尤其是对于晚期疾病。在此,对72例接受原发切除或围手术期标准治疗FLOT方案的GEJ I和II腺癌患者的福尔马林固定石蜡包埋肿瘤切片,使用多重免疫组化分析了其瘤内T细胞组成。使用Mann-Whitney U和log rank分析评估了T细胞的比例及其对生存的影响。短期和长期生存者的比较揭示了调节性T细胞(Tregs)浸润的显著差异。新辅助FLOT治疗后的肿瘤呈现CD8+ T细胞比例增加且Granzyme B表达降低,表明免疫应答发生了改变。总生存分析显示,Tregs高浸润与较差的生存相关。值得注意的是,对FLOT治疗有应答者的T细胞频率更高且生存改善,而无应答者则表现出更高水平的Tregs和表达TIM-3的CD8+ T细胞。总体而言,GEJ癌症患者在接受新辅助FLOT化疗后CD8+ T细胞增加,而Tregs与治疗应答和生存降低相关。
Gastroesophageal junction (GEJ) adenocarcinoma is an increasingly common cancer with complex biology and poor prognosis. The treatment strategy for locally advanced tumors involves multimodal treatment with perioperative chemotherapy. However, survival rates remain low, especially for advanced disease. Here, formalin-fixed paraffin-embedded tumor sections from 72 patients with GEJ I and II adenocarcinoma who underwent primary resection or perioperative standard-of-care FLOT treatment were analyzed for their intratumoral T cell composition using multiplex immunohistochemistry. The proportions of T cells and their influence on survival were evaluated using Mann-Whitney U and log rank analyses. A comparison of short- and long-term survivors revealed significant differences in the infiltration of regulatory T cells (Tregs). Tumors after neoadjuvant FLOT treatment presented increased proportions of CD8 + T cells with reduced Granzyme B expression, indicating an altered immune response. Overall survival analysis revealed that high infiltration of Tregs was associated with poor survival. Notably, responders to FLOT therapy had a greater T cell frequency and improved survival, whereas nonresponders presented higher levels of Tregs and CD8 + T cells expressing TIM-3. Overall, GEJ cancer patients had increased CD8 + T cells after neoadjuvant chemotherapy with FLOT, and Tregs were associated with treatment response and reduced survival.
MEMBER ACCOUNT
登录成功会直接打开下一页。